Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of ATRN-119, an ATR Inhibitor, in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS

NCT07617363 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07617363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07617363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of ATRN-119, an ATR Inhibitor, in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
Lead sponsor
Washington University School of Medicine
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2031
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, high-risk myelodysplastic syndrome